8R2A
 
 | | CpKRS complexed with lysine and an inhibitor | | Descriptor: | 2-azanyl-4-(trifluoromethyl)-6-[[(1~{R},3~{S})-3-(trifluoromethyl)cyclohexyl]methyl]-7~{H}-pyrrolo[3,4-d]pyrimidin-5-one, DIMETHYL SULFOXIDE, GLYCEROL, ... | | Authors: | Dawson, A, Baragana, B, Caldwell, N. | | Deposit date: | 2023-11-03 | | Release date: | 2024-10-30 | | Last modified: | 2025-07-09 | | Method: | X-RAY DIFFRACTION (2.4 Å) | | Cite: | Cryptosporidium lysyl-tRNA synthetase inhibitors define the interplay between solubility and permeability required to achieve efficacy.
Sci Transl Med, 16, 2024
|
|
8S00
 | | CpKRS complexed with lysine and an inhibitor | | Descriptor: | 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL, 6-oxidanyl-~{N}-[(1-oxidanylcyclohexyl)methyl]-4-oxidanylidene-chromene-2-carboxamide, GLYCEROL, ... | | Authors: | Dawson, A, Baragana, B, Caldwell, N. | | Deposit date: | 2024-02-13 | | Release date: | 2024-11-06 | | Last modified: | 2025-07-09 | | Method: | X-RAY DIFFRACTION (2 Å) | | Cite: | Cryptosporidium lysyl-tRNA synthetase inhibitors define the interplay between solubility and permeability required to achieve efficacy.
Sci Transl Med, 16, 2024
|
|
